產(chǎn)品詳情
簡單介紹：
重組人半乳凝素-3蛋白與其它公司提供的重組蛋白不同，rHuGalectin-3蛋白產(chǎn)品為采用CFS的無細(xì)胞麥胚蛋白合成系統(tǒng)表達(dá)出來的重組蛋白，可表達(dá)出對(duì)細(xì)胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時(shí)獨(dú)有的全自動(dòng)蛋白純化技術(shù)則簡便高效，將蛋白純化過程中對(duì)蛋白的損傷降低到*小程度.重組人半乳凝素-3蛋白（全長序列）產(chǎn)品可用于Western Blot驗(yàn)證、抗體制備、蛋白檢測(cè)、ELISA等試驗(yàn)中.
詳情介紹：
重組人半乳凝素-3蛋白
| Synonyms | AGE-R3, CBP35, GAL3, L29, LGALS3, Mac-2 |
| Species | Human |
| Accession | P17931 |
| GeneID | 3958 |
| Source | Escherichia coli. |
| Molecular Weight | 重組人半乳凝素-3蛋白Approximately 26.0 kDa, a single non-glycosylated polypeptide chain containing 249 amino acids. |
| Quantity | 10μg/50μg/1000μg |
| AA Sequence | ADNFSLHDAL SGSGNPNPQG WPGAWGNQPA GAGGYPGASY PGAYPGQAPP GAYPGQAPPG AYPGAPGAYP GAPAPGVYPG PPSGPGAYPS SGQPSATGAY PATGPYGAPA GPLIVPYNLP LPGGVVPRML ITILGTVKPN ANRIALDFQR GNDVAFHFNP RFNENNRRVI VCNTKLDNNW GREERQSVFP FESGKPFKIQ VLVEPDHFKV AVNDAHLLQY NHRVKKLNEI SKLGISGDID LTSASYTMI |
| Purity | 重組人半乳凝素-3蛋白> 98 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | Fully biologically active when compared to standard. The ED50 as determined by its ability to agglutinate human red blood cells is less than 10 μg/ml. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered solution in 1 × PBS, pH 7.4, 3mM DTT. |
| Endotoxin | Less than 0.1 EU/μg of rHuGalectin-3 as determined by LAL method. |
| Reconstitution | 重組人半乳凝素-3蛋白We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組人半乳凝素-3蛋白 | |
| SDS-PAGE |
|
| Reference |
1. J Dumic, S Dabelic, M Flogel. 2006. Biochim Biophys Acta, 1760: 616-35. 2. J Raimond, DB Zimonjic, C Mignon, et al. 1997. Mamm Genome, 8: 706-7. 3. DN Cooper. 2002. Biochim Biophys Acta, 1572: 209-31. 4. NC HendersonandT Sethi. 2009. Immunol Rev, 230: 160-71. 5. YP Yan, BT Lang, R Vemuganti, et al. 2009. Brain Res, 1288: 116-24. 6. YH Lin, LY Lin, YW Wu, et al. 2009. Clin Chim Acta, 409: 96-9. |
| Background | Human Galectin-3 also named AGE-R3, CBP35, GAL3, L29, LGALS3, Mac-2, is belonging to the galectins family and it is encoded by a single gene, LGALS3, located on chromosome 14, locus q21–q22. It is expressed in the nucleus, cytoplasm, mitochondrion, cell surface, and extracellular space. Galectin-3 is approximately 30 kDa and, like all galectins, contains a carbohydrate-recognition-binding domain (CRD) of about 130 amino acids that enable the specific binding of β-galactosides. Given Galectin-3’s broad biological functionality, it has been demonstrated to be involved in cancer, inflammation and fibrosis, heart disease, and stroke. Studies have also shown that the expression of galectin-3 is implicated in a variety of processes associated with heart failure, including myofibroblast proliferation, fibrogenesis, tissue repair, inflammation, and Ventricular remodeling. Human Galectin-3 shares 79% amino acid sequence identity with rat and mouse Galectin-3, respectively. |
